YK-4-279
CAS No. : 1037184-44-3
| Size | Price | Stock |
|---|---|---|
| 5mg | $68 | In-stock |
| 10mg | $106 | In-stock |
| 25mg | $240 | In-stock |
| 50mg | $407 | In-stock |
| 100mg | $600 | In-stock |
| 200 mg | Get quote | |
| 500 mg | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-14507 |
| M.Wt: | 366.20 |
| Formula: | C17H13Cl2NO4 |
| Purity: | >98 % |
| Solubility: | DMSO : 25 mg/mL (ultrasonic) |
YK-4-279 blocks RNA Helicase A (RHA) binding with EWS-FLI1 (oncogenic protein). YK-4-279 induces apoptosis and shows anti-proliferation activities towards various cancer cells. YK-4-279 has a chiral center and it can be separated into two enantiomers. YK-4-279 can be used for the research of cancer[1][2]. IC50 & Target: IC50: 0.94 µM (TC32), 1.83 µM (TC71), 1.03 µM (RDES), 0.33 µM (SKES), 0.94 µM (MMH-ES-1), 0.60 µM (STA-ET 7.2), 1.46 µM (A4573), 4.95 µM (PC3), 22.82 µM ( MCF7), 0.82 µM (MDA-MB-231), 1.514 µM (PANC1), 14.28 µM (ASPC1)[2] In Vitro: YK-4-279 (3-30 µM; overight) dissociates EWS-FLI1 from RHA in Ewing’s sarcoma family tumor (ESFT) cells[1]. YK-4-279 (3-30 µM; 14 h) nearly eliminates cyclin D1 in TC32 cells[1]. YK-4-279 (3-30 µM; 72 h) potently and specifically inhibits ESFTs[1]. YK-4-279 (50 µM; 6 h) induces substantial apoptosis of ESFT cells[1]. YK-4-279 (0.1-30 µM; 72 h) inhibits the growth of ESFT, prostate, breast and pancreatic cancer cells[2]. In Vivo: YK-4-279 (1.5 mg; i.p. once) inhibited ESFT tumor growth[1].
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Autem earum hic iste maiores, nam neque rem suscipit. Adipisci consequatur error exercitationem fugit ipsam optio qui, quibusdam repellendus sed vero! Debitis.
Inquiry Information- Product Name:
- YK-4-279
- Cat. No.:
- HY-14507
- Quantity:
Your information is safe with us.